Page 69 - Read Online

Li et al. Hepatoma Res. 2026;12:36 Page 15 of 15

45. Ren Z, Xu J, Bai Y, et al. ; ORIENT-32 study group. Sintilimab plus a bevacizumab biosimilar (IBI305) versus sorafenib in unresectable
hepatocellular carcinoma (ORIENT-32): a randomised, open-label, phase 2-3 study. Lancet Oncol. 2021;22:977-90. DOI PubMed
46. Qin S, Kudo M, Meyer T, et al. Tislelizumab vs sorafenib as first-line treatment for unresectable hepatocellular carcinoma: a phase 3
randomized clinical trial. JAMA Oncol. 2023;9:1651-9. DOI PubMed PMC
47. Qin S, Gu S, Chan SL, et al. ; CARES-310 Study Group. Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for
unresectable hepatocellular carcinoma (CARES-310): final analysis of a randomised, open-label, international, phase 3 study. Lancet
Oncol. 2025;26:1598-611. DOI PubMed
48. Zhao C, Zhang Y, Wang G, et al. Finotonlimab (PD-1 inhibitor) plus bevacizumab (bevacizumab biosimilar) as first-tier therapy for late-
stage hepatocellular carcinoma: a randomized phase 2/3 trial. Signal Transduct Target Ther. 2025;10:249. DOI PubMed PMC
49. Shi Y, Han G, Zhou J, et al. Toripalimab plus bevacizumab versus sorafenib as first-line treatment for advanced hepatocellular
carcinoma (HEPATORCH): a randomised, open-label, phase 3 trial. Lancet Gastroenterol Hepatol. 2025;10:658-70. DOI PubMed
50. Strebel BM, Dufour JF. Combined approach to hepatocellular carcinoma: a new treatment concept for nonresectable disease. Expert Rev
Anticancer Ther. 2008;8:1743-9. DOI PubMed
51. Kudo M, Imanaka K, Chida N, et al. Phase III study of sorafenib after transarterial chemoembolisation in Japanese and Korean patients
with unresectable hepatocellular carcinoma. Eur J Cancer. 2011;47:2117-27. DOI PubMed
52. Lencioni R, Llovet JM, Han G, et al. Sorafenib or placebo plus TACE with doxorubicin-eluting beads for intermediate stage HCC: The
SPACE trial. J Hepatol. 2016;64:1090-8. DOI PubMed
53. Meyer T, Fox R, Ma YT, et al. Sorafenib in combination with transarterial chemoembolisation in patients with unresectable
hepatocellular carcinoma (TACE 2): a randomised placebo-controlled, double-blind, phase 3 trial. Lancet Gastroenterol Hepatol.
2017;2:565-75. DOI PubMed
54. Kudo M, Ueshima K, Ikeda M, et al. Final results of TACTICS: a randomized, prospective trial comparing transarterial
chemoembolization plus sorafenib to transarterial chemoembolization alone in patients with unresectable hepatocellular carcinoma. Liver
Cancer. 2022;11:354-67. DOI PubMed PMC
55. Duan X, Li H, Kuang D, et al. Comparison of drug-eluting bead transarterial chemoembolization combined with apatinib versus drug-
eluting bead transarterial chemoembolization for the treatment of unresectable hepatocellular carcinoma: a randomized, prospective,
multicenter phase III trial. Signal Transduct Target Ther. 2024;9:304. DOI PubMed PMC
56. Peng Z, Fan W, Zhu B, et al. Lenvatinib combined with transarterial chemoembolization as first-line treatment for advanced
hepatocellular carcinoma: a phase III, randomized clinical trial (LAUNCH). J Clin Oncol. 2023;41:117-27. DOI PubMed
57. Koroki K, Ogasawara S, Ooka Y, et al. Analyses of intermediate-stage hepatocellular carcinoma patients receiving transarterial
chemoembolization prior to designing clinical trials. Liver Cancer. 2020;9:596-612. DOI PubMed PMC
58. Zhu HD, Li HL, Huang MS, et al. ; CHANCE001 Investigators. Transarterial chemoembolization with PD-(L)1 inhibitors plus molecular
targeted therapies for hepatocellular carcinoma (CHANCE001). Signal Transduct Target Ther. 2023;8:58. DOI PubMed PMC
59. Jin ZC, Chen JJ, Zhu XL, et al. ; CHANCE2201 Investigators. Immune checkpoint inhibitors and anti-vascular endothelial growth factor
antibody/tyrosine kinase inhibitors with or without transarterial chemoembolization as first-line treatment for advanced hepatocellular
carcinoma (CHANCE2201): a target trial emulation study. EClinicalMedicine. 2024;72:102622. DOI PubMed PMC
60. Liu K, Yang L, Zhang X-M, et al. HIF-1α and VEGF levels for monitoring hepatocellular carcinoma treatment response to transcatheter
arterial chemoembolization. Transl Cancer Res. 2017;6:1043-9. DOI
61. Liu K, Min XL, Peng J, Yang K, Yang L, Zhang XM. The changes of HIF-1α and VEGF expression after TACE in patients with
hepatocellular carcinoma. J Clin Med Res. 2016;8:297-302. DOI PubMed PMC

Disclaimer/Publisher’s Note: All statements, opinions, and data contained in this publication are solely those of the individual author(s) and
contributor(s) and do not necessarily reflect those of OAE and/or the editor(s). OAE and/or the editor(s) disclaim any responsibility for harm to
persons or property resulting from the use of any ideas, methods, instructions, or products mentioned in the content.

© The Author(s) 2026. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License
(https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, sharing, adaptation, distribution and
reproduction in any medium or format, for any purpose, even commercially, as long as you give appropriate credit to the original author(s) and
the source, provide a link to the Creative Commons license, and indicate if changes were made.